DELFI Diagnostics, FirstLook Lung, a pioneering blood test is revolutionizing cancer detection. This innovative assay, developed by DELFI Diagnostics, utilizes advanced fragmentomics science to scrutinize cell-free DNA (cfDNA) patterns in blood samples. By leveraging sophisticated machine learning algorithms on comprehensive whole-genome sequencing data, FirstLook Lung accurately gauges the likelihood of detecting lung cancer via low-dose CT (LDCT) scans, boasting an exceptional negative predictive value (NPV) of 99.7 percent.
Representing a paradigm shift in cancer screening, FirstLook Lung offers a convenient, accurate, and personalized approach to identifying individuals, including those with early-stage lung cancer. With its high sensitivity, the test effectively identifies most individuals who could benefit from LDCT screening. Crucially, its 99.7 percent NPV provides reassurance to those without signs of lung cancer, minimizing unnecessary anxiety and follow-up procedures.
Recognizing the pressing need to enhance lung cancer screening rates, DELFI Diagnostics strives to render cancer screening more accessible and affordable. By integrating FirstLook Lung into routine blood testing, healthcare providers can efficiently identify individuals warranting further LDCT evaluation. This proactive stance aligns with efforts to combat the underutilization of LDCT screening, particularly among marginalized communities.
DELFI Diagnostics has partnered with OSF HealthCare, a leading Midwest health system, to deploy FirstLook Lung across multiple locations in Illinois and Michigan. This collaboration aims to enhance lung cancer screening rates, especially among underserved communities.
OSF HealthCare, which currently achieves a 35 percent success rate in screening eligible patients with LDCT scans, aspires to markedly augment this figure with FirstLook Lung’s adoption. Initially available at 18 OSF HealthCare locations, the test’s accessibility is slated for expansion throughout the organization’s network.
Dr. Peter Bach, Chief Medical Officer at DELFI, underscores the test’s simplicity and efficacy, streamlining lung cancer screening and guiding informed decisions on diagnostic measures like LDCT scans.
Dr. James McGee, a radiation oncologist and founding director of the OSF HealthCare Cancer Institute, underscores the pivotal role of early detection in enhancing patient outcomes. He expresses confidence in innovative screening solutions like FirstLook Lung to positively impact lung cancer screening rates among OSF HealthCare patients.
Although financial specifics of the partnership remain undisclosed, both entities are dedicated to advancing the accessibility and efficacy of lung cancer screening. By harnessing DELFI’s cutting-edge technology and OSF HealthCare’s expansive network, this collaboration seeks to empower individuals with augmented screening options, ultimately fostering better health outcomes in the fight against lung cancer.
